Edwards SAPIEN 3 Ultra valve

Now approved for low-risk severe aortic stenosis

Low rates of pacemaker implantation[1]

Predictable positioning and low frame height while demonstrating low rates of permanent pacemaker implantation[1,2]

Future coronary access

Short frame height and open cell geometry facilitates future coronary access[3]



PVL performance

Sealing skirt designed for paravalvular leak (PVL) performance

Low-risk patients deserve the lowest-risk procedure

Give your patients SAPIEN 3 Ultra TAVI

Edwards

Low-risk patients deserve the lowest-risk procedure

SAPIEN 3 Ultra demonstrates low rates of death and stroke at 30 days.[1]

Your valve choice today can impact your patients' future

Coronary access

- Post-TAVI patients are at risk of developing coronary artery disease (CAD) following implantation[4]

Paravalvular leak

- Paravalvular leak (PVL) has been associated with long-term patient cardiovascular mortality after TAVI[5]

Conduction disturbances

- Long-term complications from pacemaker implantation negatively impact patient quality of life and mortality[6]

References:

1. STS/ACC TVT Registry, Data on File at Edwards Lifesciences.
2. Webb J, Gerosa G, Lefèvre T, Leipsic J, Spence M, Thomas M, et al. Multicenter evaluation of a next-generation balloon-expandable transcatheter aortic valve. J Am Coll Cardiol. 2014;64(21):2235–43.
3. Tarantini G, Fovino LN, Leprince P, et al. Predictors, feasibility and outcomes of coronary intervention up to 3 years after TAVI with a balloon-expandable valve: results from a large European multicenter registry. Presented at: ESC Congress 2019; September 2019; Paris, France.
4. Yudi MB, et al. Coronary Angiography and percutaneous coronary intervention after transcatheter aortic valve replacement. *JACC* Vol 71, No 12, 2018.
5. Kapadia-, S. et al. (2015). 5-year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. *The Lancet*. 385 (9986), 2485-91.
6. Fujita B, et al. Impact of new pacemaker implantation following surgical and transcatheter aortic valve replacement on 1-year outcome. *Eur J Cardiothorac Surg* 2019.

Available in 20, 23, and 26 mm sizes.
For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult eifu.edwards.com where applicable).
Edwards devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

Edwards Lifesciences • Route de l'Etraz 70, 1260 Nyon, Switzerland • edwards.com

Edwards